

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Shigeru Akasofu et al.

Application No.: 10/560,179

Confirmation No.: 7982

Filed: December 9, 2005

Art Unit: 1617

For: NEUROCYTE PROTECTIVE AGENT

Examiner: Deirdre R. Claytor

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action mailed April 23, 2007. The Examiner has required restriction to one of the following four claim groups:

Group 1: Claims 1-12, drawn to a protective agent for neurons of the central nervous system, comprising any one of the compounds shown in (i) to (vii);

Group 2: Claims 13-19, drawn to a method of protecting neurons of the central nervous system, comprising administering the protective agent of Group 1;

Group 3: Claims 21, 22, and 24-26, drawn to a method of screening for a compound with A β aggregation inhibitory effect; and

Group 4: Claims 23 and 27, drawn to a screening kit for a compound with A β aggregation inhibitory effect.

Applicant hereby elects Group 2 (claims 13-19) for prosecution on the merits. This election is made without traverse.

Applicant hereby elects 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methylpiperidine, or a pharmacologically acceptable salt thereof, as the agent species, and A β toxicity as the disorder species.


Claims 13, 14, 15, and 18 read on the elected claims and species.

Conclusion

It is believed that this paper is fully responsive to the outstanding requirement for claim and species election. Accordingly, consideration of these remarks is respectfully requested.

Dated: May 23, 2007

Respectfully submitted,

By 

Paul M. Zagar

Registration No.: 52,392
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant